Cardiovascular Systems Inc.
CSII
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
9.2% upsideUndervalued by 9.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $843.96 Million |
|---|---|
| Enterprise Value | $732.08 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.94 |
| Beta | 0.74 |
| Outstanding Shares | 39,663,565 |
Return
| Return on Equity | -15.82% |
|---|---|
| Return on Assets | -12.16% |
| Return on Invested Capital | -14.04% |
Valuation & Multiples
| P/E Ratio | -21.24 |
|---|---|
| PEG | 176.55 |
| Price to Sales | 3.33 |
| Price to Book Ratio | 3.33 |
| Enterprise Value to Revenue | 3.05 |
| Enterprise Value to EBIT | -18.98 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cardiovascular Systems Inc.
CEO: Scott Ward Relevant Senate Committees
Controls taxation, trade, and entitlement spending, including Medicare and Medicaid reimbursement rates. These rates are critically important revenue drivers for medical device manufacturers, and tax policy impacts profitability.
Allocates discretionary federal spending, directly impacting funding for healthcare programs (Medicare/Medicaid) and scientific research, which are vital for medical device companies' revenue and R&D.
Directly regulates the FDA, which is critical for medical device approval and market access. Also oversees NIH funding for research and development, and influences labor laws, all highly material to CSII.